Establish botanical identity and root use first.
The specification should identify Withania somnifera (L.) Dunal and the plant part used. “Ashwagandha extract” alone does not establish that the material comes from the root. Root and leaf differ in composition, making this distinction the first step in technical assessment.
Ask the manufacturer for botanical-source, plant-part, extract-definition and traceability documents. Match the source-root records to the resulting extract. The sample name, product code and offered commercial grade should identify the same material.
Source: NIH ODS — Ashwagandha: health professional fact sheet
Ask what “total withanolides” includes.
A single compound result and a sum of several compounds are different measurements. The method dossier should identify which compounds are included and how each is calculated. Similar percentages may have been obtained using different analytical scopes.
Published HPLC methods have assessed multiple withanolides in root and leaf. They provide an analytical basis for separating compounds and assessing their quantities. A publication does not, by itself, establish that the supplied commercial batch was tested using that method.
| Look for this in the report | What it means for selection |
|---|---|
| Analyte list | The compounds included in the total should be explicit. |
| Method and version | The applied method should be identified beyond the term HPLC. |
| Reference standards | The standards used to calculate the result should be stated. |
| Calculation basis | Distinguish dry-basis results from results reported as supplied. |
| Individual compound results | Compounds monitored separately, such as withaferin A, require their own definitions. |
Source: Chaurasiya et al. (2008) — HPLC analysis of withanolides in root and leaf
Separate the 5% target, batch result and formulation calculation.
A target of 5% total withanolides by HPLC can be a starting criterion for product development. The commercial specification defines the acceptance range, analytical scope and calculation basis; the CoA verifies the result for the sample or supplied batch. A target value and a measured result are not the same document.
In a simple mass calculation, 200 mg of an extract confirmed to contain 5% on the same weight basis corresponds to 10 mg total withanolides. This is a formulation calculation, not a daily-intake or clinical-dose recommendation. When content is reported on a dry basis, moisture information and the calculation basis also need consideration.
The extraction ratio is a separate property. A starting-material-to-extract ratio does not, on its own, determine total withanolide content or clinical efficacy. Track these properties in separate fields when comparing quotations.
Read the CoA alongside the method and laboratory scope.
Check the CoA’s product code, batch number, analysis date, units and acceptance criteria. If it reports only “complies”, establish whether the numerical result or underlying report needed for your decision is available. The sample identity should be traceable to the analytical report.
Reference materials support measurement verification and quality assurance. The standard’s identity and certificate help clarify which compounds are measured. Use of a reference material does not, by itself, verify every property or the clinical performance of a commercial extract.
At Biontera, we verify identity, content and quality characteristics for every ingredient we supply through accredited laboratory testing. We review the relevant test’s accreditation scope, method and connection to the batch documents together.
Source: NIH ODS AMRM — Reference materials for dietary supplement analysis
Distinguish content analysis from research outcomes and product suitability.
Assessment of a clinical study should include its plant part, extract, amount, duration and participant group. NCCIH notes the variety of preparations and small sample sizes in ashwagandha research. Do not transfer another formulation’s research to a new product solely because its withanolide percentage is similar.
HPLC supports analytical assessment of content. Health effects, bioavailability or equivalent doses require separate research. The intended user group, co-ingredients, labelling and target-market conditions also form part of finished-product development.
Source: NCCIH — Ashwagandha: research and safety information
Move from technical documents to a sample decision.
Start by sharing the intended dosage form, planned extract amount, manufacturing conditions and estimated annual demand. Establish the document scope first, then assess flow, blending, moisture and sensory properties in your own formulation.
Biontera brings ingredient selection, analytical planning, formulation consultancy and submission-dossier preparation into the same project workflow. Procurement decisions and formulation work can then proceed against the same specification and technical dossier.